Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Exp Neurol. 2016 Apr 9;280:89–96. doi: 10.1016/j.expneurol.2016.04.010

Figure 3.

Figure 3

Mortality in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were monitored through day 21 post infection. Data represents percent daily survival in comparison to day 0. The numbers of mice per group at day 0 were 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p<0.05, chi-square test.